Larimar Therapeutics (NASDAQ:LRMR) Announces Quarterly Earnings Results, Misses Estimates By $0.16 EPS

Larimar Therapeutics (NASDAQ:LRMR) issued its quarterly earnings data on Monday. The company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.16), Zacks reports.

Larimar Therapeutics Trading Down 10.2 %

LRMR opened at $2.28 on Tuesday. Larimar Therapeutics has a 12-month low of $2.25 and a 12-month high of $11.20. The firm has a 50 day moving average of $3.16 and a two-hundred day moving average of $5.24. The firm has a market capitalization of $145.48 million, a PE ratio of -1.98 and a beta of 0.99.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on LRMR shares. HC Wainwright restated a “buy” rating and set a $15.00 price objective on shares of Larimar Therapeutics in a research note on Friday, January 24th. Truist Financial initiated coverage on shares of Larimar Therapeutics in a research note on Wednesday, January 29th. They set a “buy” rating and a $18.00 price objective for the company. Ten analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $20.13.

Larimar Therapeutics Company Profile

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.